Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 339

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 339
---
 |               3,013 |   |     |             - |     |       - |     |                         - |   |     |              4,969 |   |
| Costs associated with share issue on February 15, 2023 |     |      |     |                   - |     |                (903 | ) |     |             - |     |       - |     |                         - |   |     |               (903 | ) |
| Shares issued on May 26, 2023                          |     |    9 |     |               2,277 |     |                   - |   |     |             - |     |     103 |     |                      (355 | ) |     |              2,025 |   |
| Costs associated with share issue on May 26, 2023      |     |      |     |                   - |     |                   - |   |     |             - |     |       - |     |                      (527 | ) |     |               (527 | ) |
| Share-based payment charge                             |     |      |     |                   - |     |                   - |   |     |             - |     |       - |     |                       141 |   |     |                141 |   |
| Total contribution by and distributions to owners      |     |      |     |               4,233 |     |               2,110 |   |     |             - |     |     103 |     |                      (741 | ) |     |              5,705 |   |
| At June 30, 2023                                       |     |      |     |               5,341 |     |              85,777 |   |     |        53,003 |     |     823 |     |                  (139,645 | ) |     |              5,299 |   |

The accompanying notes
form part of these financial statements

| F-5 |

Notes Forming Part of The Consolidated Unaudited Interim Financial Information

For the six month period ended June 30, 2024

| 1. | Basis of preparation |

The unaudited interim
consolidated financial information for the six months ended June 30, 2024 has been prepared following the recognition and measurement
principles of the International Financial Reporting Standards, International Accounting Standards and Interpretations (collectively IFRS)
issued by the International Accounting Standards Board (IASB),